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Purpose: Common genetic variation in the complement component 1 inhibitor gene (SERPING1) was recently reported
to increase the risk of developing age-related macular degeneration (AMD). This study was performed to replicate the
association between SERPING1 and AMD.
Methods: Seven single nucleotide polymorphisms (SNPs) tagging common haplotypes across SERPING1 were genotyped
on 786 (The Mayo Clinic) subjects and the association with AMD studied using single SNP and haplotype association
analyses. The SNP in intron 6 (rs2511989) previously reported to increase the risk of AMD was studied in an additional
1,541 subjects from the Age-Related Eye Disease Study (AREDS). Association with specific subtypes of AMD and
interaction  with  four  other  loci:  complement  factor  H  (CFH),  age-related  maculopathy  susceptibility  2  (ARMS2/
LOC387715), High Temperature Requirement Factor A1 (HTRA1), complement factor B/complement component 2
(CFB/C2), and complement component 3 (C3) involved in AMD was explored.
Results: The seven tag-SNPs were not associated with AMD in the Mayo subjects (p=0.13–0.70) and rs2511989 was also
not associated with AMD in the Mayo or AREDS subjects (p=0.44–0.45). Evaluation of haplotypes across SERPING1
did not reveal association with AMD (p=0.14–0.97). SNPs were not associated with AMD subtypes (early, geographic
atrophy, or exudation). No interaction with other AMD risk variants was observed.
Conclusions: We were unable to replicate the reported association between SERPING1 and AMD in two independent
groups of subjects.
Age related macular degeneration (AMD) is a leading
cause of irreversible loss of vision in older individuals [1].
Both genetic and cell biologic analyses support a role for
dysregulation  of  innate  immunity  in  the  pathogenesis  of
AMD. Extensive deposition of innate immunity proteins at the
level of Bruch’s membrane [2,3] in AMD patients has been
consistently  observed.  Genetic  variants  in  complement
pathway genes including complement factor H (CFH) [4-6],
complement factor B (CFB)/complement component 2 (C2)
[7], and complement component 3 (C3) [8-11] are established
risks for developing AMD. The association between AMD
and  genetic  variation  in  these  loci  has  been  extensively
replicated as recently reviewed [12]. Many other common
genetic variants have been proposed for AMD. However,
review  of  a  partial  list  shows  that  they  do  not  yet  have
sufficient support due to the absence of replication studies
[13-20]  or  failure  to  consistently  replicate  the  genetic
association in independent groups of subjects [21-29]. Thus,
at this time there is strong evidence for the involvement of
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genetic  variation  in  genes  of  the  alternative  pathway  of
complement  and  one  additional  locus  (LOC387715/High
Temperature  Requirement  Factor  A1  [HTRA1])  on
chromosome 10q26 [30,31].
Recently, there has been interest in exploring the genes
involved  in  classical  complement  activation  initiated  by
antibody-antigen interactions. Evidence for a possible role of
the  classical  complement  pathway  comes  from  the
observation of anti-retinal antibodies in patients with AMD
[32-35], animal models with AMD-like pathology [36], and
expression of these proteins in the aging retina and retinal
pigment epithelium (RPE) [37].
The complement component 1 (C1) inhibitor is a key
regulator of the classical pathway and has been reported to
down-regulate the alternative pathway in vitro by binding to
C3b and inhibiting binding of complement factor B to C3b
[38]. The C1 inhibitor has sequence homology with serine
protease inhibitors (SERPIN) and inhibits activation of the
classical and lectin compliment pathways by inhibiting the
protease  activity  of  complement  component  1,  r
subcomponent  (C1r),  complement  component  1,  s
subcomponent  (C1s),  and  mannan-binding  lectin  serine
peptidase 2 (MASP-2) [39,40]. The C1 inhibitor also regulates
vascular permeability by inhibiting proteases that generate
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200bradykinin  [40],  as  manifested  when  deficiency  of  C1
inhibitor results in hereditary angioedema [41-43]. Thus, C1
inhibitor is an excellent candidate gene for involvement in
AMD and retinal aging.
Since the discovery of the association between AMD and
variants  in  CFH,  the  systematic  study  of  other  genes
regulating  or  involved  in  the  alternative  pathway  of
complement activation has been productive (e.g., the study of
CFB/C2, C3 [7-11]). The systematic study of other genes
involved  in  innate  immunity  is  ongoing  in  several
laboratories. A recent study reported a protective effect on
AMD for the minor allele of a SNP (rs2511989) within intron
6 of the SERPING1 gene encoding the C1 inhibitor [13]. The
purpose of this study was to replicate the association between
SERPING1 and AMD in two independent groups of subjects.
We  performed  a  systematic  analysis  of  all  common
haplotypes (ancestral segments of DNA inherited as a block
in a population) across the SERPING1 locus and identified no
evidence for association with AMD.
METHODS
Subjects: The study was approved by the institutional review
board  of  the  Mayo  Clinic  (Rochester,  MN)  and  written
informed consent was obtained from all subjects. The Mayo
subjects were composed of 786 Caucasian individuals (476
AMD cases, 310 controls without AMD). Subjects and cases
were  obtained  from  the  same  eye  clinics  of  participating
physicians. Diagnosis was determined by review of fundus
photographs as described previously [4,44,45]. Briefly, all
subjects  diagnosed  with  AMD  had  large  drusen  (≥125
microns) with sufficient drusen area to fill a 700 micron circle
or more advanced findings. Controls had 5 or fewer hard
drusen  (<63  microns)  without  pigment  changes  or  more
advanced findings. Geographic atrophy and exudation were
defined using the Wisconsin age-related maculopathy grading
system [46]. The Mayo subjects have been graded multiple
independent  times  by  Dr.  Edwards  and  were  recently  re-
graded by Dr. Park. Replication studies were performed on
1,541 Caucasian subjects (1,241 with AMD and 300 controls
without  AMD)  from  the  Age-Related  Eye  Disease  Study
(AREDS) that were graded as reported previously [47]. The
final AREDS phenotype grade was used. All control grades
(controls  and  control  questionable  1–4)  were  treated  as
controls. Early AMD consisted of all grades of large drusen
(large drusen and large drusen questionable 1–3). Review of
genotype frequencies for the control questionable and large
drusen questionable AREDS subjects at known AMD risk
variants showed that the questionable groups closely matched
their  assigned  group  (e.g.,  for  the  C3  SNP  rs2230199,
genotype frequencies were within 1% when the questionable
control or large drusen categories were excluded). Further, the
maximal  difference  in  genotype  frequencies  for  the
SERPING1 SNP rs2511989 was 0.03.
Advanced  AMD  AREDS  subjects  consisted  of  all
advanced AMD grades (questionable advanced, neovascular,
geographic atrophy, and both neovascular and geographic
atrophy). Mayo or AREDS subjects with both neovascular and
geographic atrophy were included in the analysis for each
subtype, except when the analytical model required a unique
grade. When a unique grade for each subject was required, the
subjects graded both were added to the grade with a smaller
number of subjects (geographic atrophy) to increase power.
Individual SNP analyses were done with and without both,
and no differential effect was observed. Eighty-seven subjects
with the questionable advanced AMD grade only were used
for any AMD versus control analyses. Note that the number
of subjects shown in the tables may be less than the total
number  of  subjects  available  for  study,  due  to  failed
genotyping. No detectable substructure has been observed
within  the  Mayo  subjects  that  might  inflate  case-control
statistics, and the small amount of sub-structure within the
AREDS subjects had no effect on the individual SNP case-
control statistics. Demographic and phenotypic information
for the Mayo and AREDS subjects is provided in Table 1.
*Eighty-seven AREDS subjects with the “questionable advanced age-related macular degeneration (AMD)” grade were used
as described in Methods, but are not included in this table. **29 Mayo subjects and 85 AREDS subjects who had both geographic
atrophy and exudative AMD (category “Both”) were included in the geographic atrophy group as described in the Methods.
Abbreviations: SD is standard deviation.
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TABLE 1. DEMOGRAPHIC AND PHENOTYPIC FEATURES OF THE MAYO AND AREDS SUBJECTS
Category
Mayo subjects                                                                               AREDS subjects
Age 
Number                (Mean±SD)
Male:Female                                                     Age
ratio                        Number                (Mean±SD)
Male:Female
ratio
Control subjects 310 69.5±8.2 0.83 300 77.6±4.3 0.79
AMD subjects* 476 76.9±9.6 0.55 1241 79.9±5.1 0.68
Early AMD 218 73.7±10.3 0.46 583 79.0±4.9 0.65
Exudation 161 79.2±8.7 0.59 324 80.6±5.0 0.76
Geographic
atrophy**
97 80.2±6.6 0.70 247 80.8±5.3 0.65Selection of tag and functional SNPs: SNPs genotyped in the
international  haplotype  map  (HapMap)  [48]  were  used  to
select tag SNPs. SNPs across SERPING1 including 5 kb up
and downstream were evaluated for linkage disequilibrium
(LD) using ldSelect [49] and a custom algorithm for tag-SNP
selection was developed so that a single tag SNP would be
selected for each LD bin. Only those SNPs deemed candidate
tag-SNPs by ldSelect with a minor allele frequency (MAF) of
greater  than  or  equal  to  0.05  were  considered  for  further
selection. Tag-SNPs were ultimately selected based upon a
functional ranking system wherein non-synonymous coding
SNPs  were  preferentially  selected  among  the  tag-SNP
candidates in each LD bin, followed by synonymous coding
SNPs, SNPs from 5′ untranslated regions (UTRs), SNPs from
3′ UTRs, and finally SNPs from intronic regions. Seven SNPs
were required to tag the SERPING1 haplotypes and were
selected for genotyping.
Genotyping: The seven tag-SNPs were genotyped on genomic
DNA  extracted  from  peripheral  blood  leukocytes  using
TaqMan assays. Clustering of genotypes was inspected for
separation between genotypes and accuracy of genotype calls.
Quality  control  for  genotype  call  was  assessed  by
concordance for the control CEPH trio DNA replicates and
two sample replicates within each 96 well plate. Randomly
selected cases (25 subjects) and controls (25 subjects) were
subjected to bi-directional DNA sequencing to determine the
accuracy of genotyping with rs2511989 in a masked fashion.
Statistics: Upon receipt of genotype intensities and processing
as described above, all SNPs were noted to be in Hardy–
Weinberg  equilibrium.  Single  SNP  analyses  on  genotype
distributions were performed in SAS version 8 (SAS Institute,
Cary, NC) using logistic regression assuming a log-additive
genetic model where SNPs were coded as 0, 1, or 2 for the
number of minor alleles and the corresponding p-values were
calculated based on the score test statistics. Fisher’s exact tests
were also performed on genotype distributions. Haplotype
analyses were completed using the score test that consisted of
the  seven  SNPs  across  SERPING1.  We  also  performed
haplotype analysis with a 3-SNP-sliding-window approach,
as implemented in haplo.stats [50] using R statistical software.
Interaction effect between SERPING1 SNPs and smoking
status (defined as ever, never) on AMD status was evaluated
under a log-additive model with logistic regression using two
main effect terms (genotype for each SNP and smoking status)
and their interaction term, and assessed by a likelihood ratio
test. We also evaluated interaction between SERPING1 SNPs
and  other  major  genetics  risks  for  AMD  including
complement factor H (CFH, Y402H), LOC387715/HTRA1
(tagging SNP A69S), CFB/C2 (CFB, L9H; C2, rs547154),
and C3 (R102G and P314L). To investigate the effect of the
seven SNPs of SERPING1 including rs2511989 on AMD
subtypes, likelihood ratio tests were performed considering
controls as baseline. Haplotype analyses for AMD subtypes
were  also  performed  using  a  likelihood  ratio  test.  Age  is
confounded with diagnosis (i.e., the cases are older than the
controls), thus correction for age might reduce any detectable
genetic effect and was not employed. Nominal p-values are
reported.
RESULTS
Association between individual SNPs and AMD in the Mayo
subjects:  None  of  the  seven  SNPs  tagging  SERPING1
haplotypes (including rs2511989) were associated with AMD
subjects  compared  to  controls  without  AMD  (Table  2).
Because  of  the  previously  reported  association  between
rs2511989 and AMD, we sought to determine the accuracy of
genotyping  using  DNA  sequencing.  The  genotype  for  50
subjects determined by DNA sequencing was in complete
agreement with the TaqMan assay genotype calls. Thus, the
absence of association could not be explained by inaccurate
genotyping.
Linkage disequilibrium: To verify that our genotyping results
were similar to other Caucasian populations genotyped across
SERPING1,  we  compared  the  pattern  of  linkage
disequilibrium (LD) in the Mayo subjects to the international
HapMap  Caucasian  subjects  using  Haploview  [48,51].
Moderate to high LD was observed across the SERPING1
locus and a similar pattern was present in the Mayo subjects
and  HapMap  Caucasian  subjects  (Figure  1).  The  similar
pattern of LD further supports the accuracy of genotyping of
all seven SNPs in the Mayo subjects.
Haplotype  studies:  Comparison  of  haplotypes  across  the
SERPING1 locus in the Mayo subjects and the international
HapMap Caucasian subjects showed a similar distribution of
haplotypes (Table 3). Further, no haplotype was associated
with AMD in the Mayo subjects (p=0.14–0.97, Table 3). A 3-
SNP  sliding  window  analysis  did  not  reveal  association
between the SERPING1 haplotypes and AMD (p=0.13–0.67).
Replication  study:  Given  the  demonstrated  accuracy  of
genotyping,  we  sought  to  determine  if  the  absence  of
association could be due to a type II error arising in the Mayo
subject  group.  The  most  highly  associated  variant  in  the
previous report (rs2511989) was genotyped on 1,541 AREDS
subjects (Table 4) and no association with AMD was observed
(p=0.45).
AMD  subtype  analysis:  To  determine  if  the  absence  of
association between AMD and rs2511989 could be due to
differences  in  the  distribution  of  AMD  subtypes  in  the
different subject groups, we stratified the AMD subjects into
early  AMD,  primary  geographic  atrophy,  and  exudation.
Subgroup analysis using the seven tag-SNPs genotyped on the
Mayo subjects revealed no evidence for association with any
AMD  subtype  (early  AMD,  p=0.43–0.88;  geographic
atrophy, p=0.13–0.96; exudation, p=0.05–0.66). Similarly, no
association between rs2511989 genotypes and AMD subtypes
were observed in the AREDS subjects (p=0.17–0.97). No
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203haplotype was consistently associated with any AMD subtype
(p=0.09–0.98).
Interaction with other genetic risks for AMD: We further
sought to determine if the absence of an effect of rs2511989
on AMD risk might be explained by differences between
modifiable risk factors and other genetic risks for AMD in the
Mayo subjects. We observed no interaction between smoking
categorized  as  ever  or  never  and  SERPING1  SNPs  using
logistic  regression  (p=0.25–0.52).  We  also  found  no
interaction (p=0.68–0.98) between rs2511989 and other major
genetics  risks  for  AMD  including  complement  factor  H
(CFH,  Y402H),  ARMS2/HTRA1  (tagging  SNP  A69S),
complement  components  CFB/C2  (CFB,  L9H;  C2,
rs547154), and C3 (R102G and P314L).
DISCUSSION
We  were  unable  to  replicate  the  previously  reported
association  between  SERPING1  and  AMD  using  two
independent  groups  of  subjects  [13].  Our  study
comprehensively assessed common variation in SERPING1
and specifically the SNP (rs2511989) most highly associated
with AMD in the previous study [13].
The previous study observed several SNPs (rs2244169,
rs2511990,  rs2509897,  rs2511989,  rs2511988,  and
rs1005510)  across  SERPING1  that  were  associated  with
AMD  [13].  We  genotyped  three  of  these  SNP
(rs2509897,rs2511990,  and  rs2511989)  and  observed  no
association with AMD. Although some investigators have felt
that observing association from SNPs near the initial disease
associated  SNP  provides  additional  support  for  the
Figure 1. Linkage disequilibrium (LD) across the SERPING1 locus in HapMap (left) and Mayo subjects (right). A similar LD pattern was
observed for the two independent groups of Caucasian subjects. Numbers in the squares represent r2 estimates, while colors represent D’
estimates (from none or white, to complete or red).
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TABLE 3. SERPING1 HAPLOTYPES OBSERVED IN THE MAYO SUBJECTS AND CAUCASIAN SUBJECTS FROM THE INTERNATIONAL HAPMAP PROJECT
Haplotype                                        Frequency                                         Association with AMD in Mayo subjects
  Mayo                Mayo
HapMap                cases                controls Odds ratio (95% CI)
Simulated
   p-value
GTCGTAG 0.395 0.347 0.368 Reference 0.436
CCCAGGG 0.325 0.320 0.317 1.064 (0.828–1.368) 0.966
CTCGGGA 0.071 0.127 0.102 1.330 (0.934–1.894) 0.137
CCCGGGA 0.062 0.098 0.120 0.902 (0.642–1.267) 0.189
Haplotypes with a frequency of 5% or higher are shown. The single-nucleotide polymorphism (SNP) order (left to right) is the
same as in Table 1. Haplotypes across the SERPING1 locus were tested for association with age-related macular degeneration
(AMD) in the Mayo subjects and none was observed.association, we have observed otherwise [11]. This situation
arises  secondary  to  linkage  disequilibrium  and  supports
accurate genotyping, but does not protect against a type I error
[11].
We recognize that a particular group of subjects may miss
a valid association (type II error) or show false association
(type  I  error).  Several  causes  for  such  observations  exist
including invalid genotyping, population stratification, non-
random  sampling  of  the  underlying  population,  and
differences  in  non-randomized  features  of  the  cases  and
controls  such  as  disease  subtypes.  For  these  reasons,  we
validated the genotyping with a second independent assay,
studied two independent populations, and extensively studied
the disease subgroups and similarities between our Caucasian
populations and those genotyped elsewhere (HapMap). All of
these analyses supported the validity of our study and failed
to provide evidence for an effect of SERPING1 SNPs on
AMD. Genotyping of additional groups of subjects will be
required to determine if SERPING1 SNPs are associated with
AMD in selected populations. Nonetheless, a major effect on
AMD is unlikely.
Genotyping  errors  can  reduce  power  and  are  thus  of
particular concern in a study that fails to replicate a previous
observation. The previous study used an Illumina BeadChip
platform in one group of subjects and an assay on demand
TaqMan method in a second independent group of subjects
[13] for genotyping rs2511989 (Table 4). Eight additional
SNPs  were  genotyped  using  a  third  (KBioscience,
Hoddesdon,  UK)  platform.  Thus,  genotyping  errors  seem
unlikely to have caused a type I error in the previous report.
We employed the same genotyping assay (TaqMan, Foster
City, CA) used on one of their subject groups on both of our
groups of subjects and performed DNA sequencing to confirm
genotyping results. Genotyping problems seem unlikely to
explain the differences between the studies.
SERPING1 is expressed in the neural retina, RPE, and
choroid of humans [13] and is likely to play a role in regulating
the complement system in the eye. Mutations in SERPING1
cause  hereditary  angioedema,  but  there  is  no  known
phenotypic overlap with AMD such as had been established
with  atypical  hemolytic  uremic  syndrome  or
glomerulonephritis arising in patients with mutations in CFH
[52]. In summary, we were unable to replicate the association
between genetic variation in SERPING1 and AMD in two
large and well characterized Caucasian subject groups and no
compelling biologic evidence is available to support a role for
the C1 inhibitor in AMD at this time.
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